NCT06575075 Pilot Study of RR-HNK in OCD
| NCT ID | NCT06575075 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Carolyn Rodriguez |
| Condition | Obsessive-Compulsive Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 45 participants |
| Start Date | 2026-01-23 |
| Primary Completion | 2028-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 45 participants in total. It began in 2026-01-23 with a primary completion date of 2028-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to understand how RR-HNK works in the brain to bring about a reduction in OCD symptoms.
Eligibility Criteria
Inclusion Criteria: * Ages 18-65 * Meet the criteria for OCD diagnosis * Failed at least 1 prior trial of standard first-line OCD treatment (e.g. SRI/CBT) or or had refused these treatments for individual reasons * Agree to the following lifestyle modifications: comply with requirements for fasting prior to --the infusion session, not enroll in any other interventional clinical trials during the duration of the study, and commit to medication study procedures. * Able to provide informed consent Exclusion Criteria: * Allergy or hypersensitivity to ketamine * Any current or past medical/psychiatric condition that makes participation unsafe in the opinion of the investigator or study physician * Pregnant or nursing, or able to become pregnant and are not practicing an effective means of birth control * Lifetime history of deep brain stimulation
Contact & Investigator
Carolyn Rodriguez, MD, PhD
PRINCIPAL INVESTIGATOR
Stanford University
Frequently Asked Questions
Who can join the NCT06575075 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Obsessive-Compulsive Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06575075 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06575075 currently recruiting?
Yes, NCT06575075 is actively recruiting participants. Contact the research team at ocdresearch@stanford.edu for enrollment information.
Where is the NCT06575075 trial being conducted?
This trial is being conducted at Palo Alto, United States.
Who is sponsoring the NCT06575075 clinical trial?
NCT06575075 is sponsored by Carolyn Rodriguez. The principal investigator is Carolyn Rodriguez, MD, PhD at Stanford University. The trial plans to enroll 45 participants.